Log in with your email address username.


Attention doctorportal newsletter subscribers,

After December 2018, we will be moving elements from the doctorportal newsletter to MJA InSight newsletter and rebranding it to Insight+. If you’d like to continue to receive a newsletter covering the latest on research and perspectives in the medical industry, please subscribe to the Insight+ newsletter here.

As of January 2019, we will no longer be sending out the doctorportal email newsletter. The final issue of this newsletter will be distributed on 13 December 2018. Articles from this issue will be available to view online until 31 December 2018.

[Comment] Large-scale screening for somatic mutations in lung cancer

Lung cancer is the leading cause of cancer-related death worldwide. More than 85% of cases are classified as non-small-cell lung cancer (NSCLC), with predicted 5-year survival of 16%. However, technological advances in the past decade, including the introduction of next-generation sequencing, have allowed for identification of several genetic mutations.1 These mutations are considered to be actionable oncogenic drivers (ie, treatable with specific drugs) since they cause specific subclasses of NSCLC, and therefore can be targeted with selective inhibitors.